Please assess the completion status of the following clinical trial:

Trial Title: Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of cystic fibrosis~2. 8 years of age or greater~3. Chronic or intermittent infection with Pseudomonas aeruginosa as defined by the Leeds Criteria~4. Pulmonary exacerbation as defined by Fuchs et al.~Exclusion Criteria:~1. Admission for greater than 48 hours prior to enrollment~2. Isolation of Burkholderia spp. in a respiratory tract culture in the prior 12 months~3. Current treatment for allergic bronchopulmonary aspergillosis~4. Pregnant or breast feeding~5. History of solid organ transplantation~6. Renal impairment at time of randomization (\< 40 mL/min as calculated by the Cockcroft-Gault equation24 ¬for adults or the Schwartz equation45 for those \< 18 years of age) or receipt of hemodialysis~7. Allergy to study medication

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intermittent Infusion piperacillin-tazobactam (Type: ACTIVE_COMPARATOR): Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams), divided in four equal doses, administered over 30 minutes, four times a day
- Continuous infusion piperacillin-tazobactam (Type: EXPERIMENTAL): Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams) as a continuous infusion over 24 hours, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).